No Data
Earnings Preview: CITIC SEC to Report Financial Results on March 26
Full text | Tencent Q4 Earnings Conference transcript: Chinese companies pay more attention to efficient use of GPUs, DeepSeek is a prime example.
On the evening of March 19, TENCENT (HKEX: 00700) released its Earnings Reports for the fourth quarter and the full year ended December 31, 2024. In the fourth quarter, revenue was 172.4 billion yuan, a year-on-year increase of 11%. Profit attributable to equity holders was 51.3 billion yuan, a year-on-year increase of 90%. Under non-international financial reporting standards, profit attributable to equity holders was 55.3 billion yuan, a year-on-year increase of 30%. For the full year 2024, revenue was 660.3 billion yuan, a year-on-year increase of 8%. Profit attributable to equity holders was 194.1 billion yuan, a year-on-year increase of 68%. Under non-international financial reporting standards, equity.
CITIC Securities to Announce 2024 Annual Results With Investor Webcast
CITIC SEC (06030.HK) plans to hold the 2024 annual performance press conference on March 27.
Gelonghui announced on March 19 that CITIC SEC (06030.HK) will hold a performance briefing via live streaming to help investors gain a more comprehensive understanding of the company's performance and operations for the year 2024. The meeting will address common concerns from investors within the scope of permissible information disclosure. The meeting is scheduled for March 27, 2025 (Thursday) from 9:00 to 10:00.
CITIC SEC (06030): CITIC SEC International provided a guarantee for the 70 million dollar notes issued by CSI MTN Limited.
CITIC SEC (06030) announced that its wholly-owned overseas subsidiary CITIC SEC International's subsidiary CSI ...
CITIC SEC: Initiates a "Buy" rating for SINOPHARM with a Target Price of 27 HKD.
CITIC SEC released a Research Report stating that it is initiating coverage on SINOPHARM (01099) with a "Buy" rating and a 9x PE for 2025, corresponding to a Target Price of 27 HKD. The report states that SINOPHARM is a leading enterprise in the domestic Pharmaceutical distribution industry, with its core Business of pharmaceutical distribution maintaining steady growth against the backdrop of increasing industry concentration; the company's medical instruments Sector is gradually increasing its share, actively introducing medical manufacturing Business while continuously expanding market coverage and cooperation channels, and laying out an edge in advanced medical instruments such as fluorescence endoscopes and imaging equipment. As regulatory impacts on the industry clear, the performance of the company's medical instruments Sector is expected to resume growth; retail
Mr Careful : this stock is quite strong. did not fall much. BYD falls like a rock.
ValueBull OP Mr Careful : it's a net cash company that is trading BELOW ITS NET CASH PER SHARE. this is getting the business for free
Mr Careful ValueBull OP : no worries. I dont short this counter.